Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,474 | 4,229 | 107 | 568 | 1,835 |
| Other current assets | 0 | 3 | 5 | 4 | 8 |
| TOTAL | $2,664 | $4,349 | $226 | $671 | $1,995 |
| Non-Current Assets | |||||
| PPE Net | 7 | 1 | 1 | 2 | 2 |
| TOTAL | $7 | $1 | $1 | $2 | $2 |
| Total Assets | $2,672 | $4,350 | $227 | $673 | $1,997 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 381 | 753 | 1,174 | 978 | 140 |
| Accrued Expenses | 62 | N/A | 38 | 36 | N/A |
| Other current liabilities | 300 | 376 | 944 | 653 | 831 |
| TOTAL | $787 | $1,211 | $2,155 | $1,667 | $971 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,434 | 1,285 | 1,167 | 709 | 478 |
| TOTAL | $1,434 | $1,285 | $1,167 | $709 | $478 |
| Total Liabilities | $2,221 | $2,496 | $3,322 | $2,376 | $1,449 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,400 | 1,000 | 958 | 733 | 733 |
| Common Shares | 288 | 250 | 183 | 183 | 183 |
| Retained earnings | -38,734 | -37,232 | -35,935 | -34,515 | -32,173 |
| TOTAL | $451 | $1,853 | $-3,094 | $-1,703 | $548 |
| Total Liabilities And Equity | $2,672 | $4,350 | $227 | $673 | $1,997 |